Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited ( (HK:2096) ) just unveiled an announcement.
Simcere Pharmaceutical Group Limited has received a further US$40 million milestone payment from AbbVie under their option-to-license agreement for SIM0500, an investigational trispecific antibody for multiple myeloma targeting GPRC5D, BCMA and CD3. The payment, which follows an earlier upfront fee and forms part of a broader deal that could be worth up to US$1.055 billion plus tiered royalties, underscores the progress of the joint clinical development program for SIM0500 and provides additional non-dilutive funding, strengthening Simcere’s financial position and validating its T-cell engager technology platform in the competitive oncology therapeutics landscape.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation- and R&D-driven pharmaceutical company that has established a State Key Laboratory of Neurology and Oncology Drug Development. It focuses on therapies in neuroscience, oncology, autoimmune diseases and anti-infective areas, targeting current and future high unmet clinical needs, and complements its in-house research with strategic partnerships with innovative companies and research institutes.
Average Trading Volume: 7,916,740
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.34B
Find detailed analytics on 2096 stock on TipRanks’ Stock Analysis page.